Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
North China Pharmaceutical Company Ltd. (600812.SS)
Shijiazhuang, CN
North China Pharmaceutical Company Ltd. is a Chinese firm specializing in the chemical pharmaceutical sector. Its extensive product range primarily features anti-infective medications, supplied as active pharmaceutical ingredients (APIs), their intermediates, and final preparations. The company's offerings further encompass biotechnological therapeutics, drugs for cardiovascular conditions, immunomodulators, vitamin-based consumer health products, and specialized pharmaceuticals for agricultural and veterinary applications. Founded in 1953, North China Pharmaceutical Company Ltd. maintains its headquarters in Shijiazhuang, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.34% | -2.99% | -12.86% | -18.64% | -21.72% | -17.90% | -25.21% | -24.58% | -57.61% | -27.01% | +98.25% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-6.4% Q1'26: -16.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+48.7% ★ Q1'26: -39.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.2% Q1'26: +1.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+7.8% Q1'26: +5.9% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.8% Q1'26: +2.2% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%0.0% ★ Q1'26: +1.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×4.95× Q1'26: 22.89× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
9.87B
est: 9.91B (-0.4%)
|
9.24B
est: 10.44B (-11.5%)
|
11.09B
11.09B – 11.09B
+6.2% YoY
|
8.72B
8.72B – 8.72B
-21.4% YoY
|
| EBITDA |
1.46B
est: 1.39B (+5.3%)
|
1.66B
est: 1.46B (+13.8%)
|
1.55B
1.55B – 1.55B
+6.2% YoY
|
1.22B
1.22B – 1.22B
-21.4% YoY
|
| EBIT |
672.93M
est: 628.97M (+7.0%)
|
718.96M
est: 662.57M (+8.5%)
|
703.87M
703.87M – 703.87M
+6.2% YoY
|
553.56M
553.56M – 553.56M
-21.4% YoY
|
| Net Income |
126.99M
est: 178.40M (-28.8%)
|
183.06M
est: 188.73M (-3.0%)
|
274.52M
274.52M – 274.52M
+45.5% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
2.00B
est: 2.08B (-3.8%)
|
1.16B
est: 2.19B (-47.2%)
|
2.33B
2.33B – 2.33B
+6.2% YoY
|
1.83B
1.83B – 1.83B
-21.4% YoY
|
| EPS |
0.07
est: 0.10 (-28.8%)
|
0.11
est: 0.11 (+0.0%)
|
0.16
0.16 – 0.16
+45.5% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 4/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 2/5 | 3/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 219.4K | 0.39% |
| 2 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 10.8K | 0.44% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 136.3K | 0.29% |
| 4 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 25.5K | 0.46% |
| 5 | Invesco FTSE All-World UCITS ETF FTWG.L | 0.00% | 50.3K | 0.15% |
| 6 | Invesco FTSE All-World UCITS ETF FWRA.SW | 0.00% | 50.4K | 0.15% |
| 7 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 55.9K | 0.17% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 55.9K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.2K | 0.48% |
| 10 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 20.7K | 0.26% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Li Xin Wang | Chairman of the Board of Directors & GM | — | male |
| Rong Liang Liu | Deputy General Manager | — | male |
| Zhang Min | Deputy General Manager | — | male |
| Zhi Gang Duan | Deputy General Manager | — | male |
| Zhiguang Xiao | Chief Accountant, Secretary of Board of Directors & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600812.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
